Disease Domain | Count |
---|---|
Neoplasms | 2 |
Infectious Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Therapeutic vaccine | 2 |
DNA vaccine | 2 |
Vaccine | 1 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date25 May 2023 |
Sponsor / Collaborator |
Start Date14 Sep 2022 |
Sponsor / Collaborator |
Start Date20 Feb 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Glioblastoma DNA vaccine(Vical, Inc.) | Glioblastoma More | Phase 2 |
VCL-HM01 | Herpes Simplex More | Phase 2 |
SNP 7/8a | Neoplasms More | Preclinical |
Cytofectins(Genzyme Corp.) ( chloride channel ) | Cystic Fibrosis More | Discontinued |
VL-2397 | Acute Lymphoblastic Leukemia More | Discontinued |